Oncology

News

J&J's subcutaneous Rybrevant cleared by FDA

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

News

AstraZeneca and Daiichi Sankyo logos next to Datroway box

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

Oncology

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

News

Enhertu moves into frontline breast cancer treatment

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

J&J's subcutaneous Rybrevant cleared by FDA

Datroway filed for TNBC in EU after data delay

Padcev/Keytruda scores again in early bladder cancer

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Enhertu moves into frontline breast cancer treatment

J&J claims FDA's latest national priority voucher

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

Oncology

Editor's Picks